Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the intergroup rhabdomyosarcoma study group

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 4, 2001, Pages 225-233

  Breitfeld, Philip P ^b   Lyden, Elizabeth ^d   Beverly Raney, R ^b   Teot, Lisa A ^c   Wharam, Moody ^c   Lobe, Thom ^c   Crist, William M ^b   Maurer, Harold M ^c   Donaldson, Sarah S ^c   Ruymann, Frederick B ^b   Anderson, James R ^a   Andrassy, Richard J ^a   Arndt, Carola A S ^a   Scott Baker, K ^a   Barr, Frederic G ^a   Archie Bleyer, W ^a   Breitfeld, Philip ^a   Breneman, John C ^a   Bridge, Julia ^a   Brown, Kenneth ^a   Grier, Holcombe E ^a   Hawkins, Douglas ^a   Houghton, Peter J ^a   Link, Michael ^a   Meyer, William H ^a   Michalski, Jeff ^a   Murphy, Sharon ^a   Paidas, Charles N ^a   Pappo, Alberto S ^a   Parham, David M ^a   Qualman, Stephen J ^a   Robison, Leslie ^a   Sandler, Eric ^a   Smith, Lynn ^a   Sorensen, Poul H B ^a   Teot, Lisa ^a   Triche, Timothy ^a   Vietti, Teresa J ^a   Walterhouse, David ^a   Wiener, Eugene S ^a   Wolden, Suzanne ^a   Womer, Richard ^a   Leeson, Joan L ^e   more..

^a Children’s Cancer Group ^*

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c Pediatric Oncology Group   (United States)

^d Pediat Intergroup Stat Office   (United States)

^e NONE   (United States)

Author keywords

Chemotherapy; Children; Etoposide; Ifosfamide; Melphalan; Metastatic; Rhabdomyosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; VINCRISTINE;

ADOLESCENT; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOSARCOMA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; BRONCHIOLITIS OBLITERANS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; INFANT; KIDNEY DISEASES; LIFE TABLES; MALE; MELPHALAN; NEOPLASM METASTASIS; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; RHABDOMYOSARCOMA; SEPSIS; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0034994886     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200105000-00010     Document Type: Article

References (26)

1. Crist W, Anderson J, Maurer H, et al. Preliminary results for patients with local/regional tumors treated on the Intergroup Rhabdomyosarcoma Study-IV (1991-97). Proc Am Soc Clin Oncol 1999; 18:555a.
2. Maurer H, Beltangady M, Gehan E, et al. The Intergroup Rhabdomyosarcoma Study-I. Cancer 1988; 61:209-20.
3. Crist W, Garnsey L, Beltangady M, et al. Prognosis in children with rhabdomyosarcoma: A report of the Intergroup Rhabdomyosarcoma Studies I and II. J Clin Oncol 1990; 8:443-52.
4. Crist W, Gehan E, Ragab A, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13:610-30.
5. Sandler E, Lyden E, Ruymann F, et al. Efficacy of ifosfamide (IFOS) and Doxorubicin (DOX) given as a Phase II " window” in children with newly diagnosed metastatic rhabdomyosarcoma (RMS): A report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Proceedings of ASCO 1999; 18:2167.
6. Houghton J, Houghton P, Green A. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. Cancer Res 1982; 42:535-9.
7. Miser J, Kinsella T, Triche T, et al. Ifosfamide with Mesna uroprotection and Etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987; 5:1191-8.
8. Kung F, Pratt C, Vega R, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors in childhood. Cancer 1993; 71:1898-903.
9. Pappo A, Etcubanas E, Santana V, et al. A Phase II trial of Ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. Cancer 1993; 71:2119-25.
10. Arndt C, Tefft M, Gehan E, et al. A feasibility, toxicity, and early response study of Etoposide, Ifosfamide, and Vincristine for the treatment of children with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study (IRS) IV Pilot Study. J Pediatr Hematol Oncol 1997; 19:124-9.
11. Houghton J, Cook R, Lutz P, et al. Childhood rhabdomyosarcoma xenografts: Responses to DNA-interacting agents and agents used in current clinical therapy. Eur J Cancer Clin Oncol 1984; 20:955-60.
12. Houghton J, Cook R, Lutz P, et al. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep 1985; 69:91-6.
13. Horowitz M, Etcubanas E, Christensen M, et al. Phase II testing of Melphalan in children with newly diagnosed rhabdomyosarcoma: A model for anticancer drug development. J Clin Oncol 1988; 6:308-14.
14. Qualman S, Coffin C, Newton W, et al. Intergroup Rhabdomyosarcoma Study: Update for pathologists. Pediatr Dev Pathol 1998; 1:550.
15. Kaplan G, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
16. Peto R, Pike M, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples. Br J Cancer 1977; 35:1-39.
17. Gertz M, Lacy M, Inwards D, et al. Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplant 1997; 20:375-80.
18. Botnick L, Hannon E, Hellman S. Multisystem stem cell failure after apparent recovery from alkylating agents. Cancer Res 1978; 38:1942-7.
19. Ortega J, Donaldson S, Ivy S, et al. Venoocclusive disease of the liver after chemotherapy with Vincristine, Actinomycin D, and Cyclophosphamide for the treatment of rhabdomyosarcoma. Cancer 1997; 79:2435-9.
20. Fisher D, Peters W. Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy. Curr Opin Hematol 1994; 1:221-7.
21. van Os R, Robinson S, Sheridan T, et al. Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents. Blood 1998; 92:1950-6.
22. Hornung R, Longo D. Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood 1992; 80:77-83.
23. Maze R, Hanenberg H, Williams D. Establishing chemoresistance in hematopoietic progenitor cells. Mol Med Today 1997; 3:350-8.
24. Anderson J, Ruby E, Link M, et al. Identification of a favorable subset of patients (pts) with metastatic (MET) rhabdomyosarcoma (RMS): a report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Proc Am Soc Clin Oncol 1997;16:510a(1836).
25. Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999; 17:2796-803.
26. Goletz T, Zhan S, Pendleton CD, et al. Cytotoxic T cell responses against the EWS/FLI-1 Ewing’s sarcoma fusion protein and the PAX3/FKHR alveolar rhabdomyosarcoma fusion protein. Proc Annu Meet Am Assoc Cancer Res 1996; 37:A3243.